The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination…
featured news
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
The Vall d’Hebron Institute of Oncology (VHIO) has received one of the COFUND grants under the Marie Skłodowska-Curie Actions (MSCA)…
“Maestra con clase” is an initiative created by Mónica Tribó to design materials and products specifically for teachers. In her…
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
The third edition of the VHIOVida Festival, which was held on Saturday October 19, in Cabrils, brought together more than…
On the weekend of 19 and 20 October, the massive solidarity initiative Pink Run Palau and Pink Run Mir was…
The Severo Ochoa Digital Oncology Unit (SOUND) is a transversal unit created at the Vall d’Hebron Institute of Oncology (VHIO)…
